Type I Diabetes
Type 1 Diabetes
DiscoveryActive
Key Facts
About Genclis
Genclis is a biotechnology company pioneering a novel drug discovery and development platform based on Transcription Infidelity (TI), a biological mechanism that generates immunologically active variant proteins from mRNA. Its pipeline includes programs in veterinary and human allergies, severe COVID-19, Type 1 Diabetes, and Lou Gehrig's disease (ALS), with its veterinary allergy candidate appearing most advanced. The company is privately held, led by co-founder and CEO Bernard Bihain, and operates with a cautious, capital-efficient business model focused on robust preclinical de-risking before clinical advancement.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |